Fæno- eller genotypetest for dihydropyrimidindehydrogenase-mangel før fluoropyrimidinbehandling

Stig Ejdrup Andersen, Niels Herluf Paulsen, Per Pfeiffer, Camilla Qvortrup, Per Damkier

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


Some patients may have partial or complete deficiency of dihydropyrimidin dehydrogenase (DPD) and be more likely to experience severe toxicity with 5-fluorouracil. Since the spring of 2020, the Danish Medicines Agency has recommended genotype or phenotype testing before treatment with a fluoropyrimidine, but the most appropriate test strategy is debated. In this review, we present polymorphisms in the genes coding for DPD and summarise the evidence for DPD-enzyme deficiency testing and pharmacokinetic guided dosing.
Bidragets oversatte titelPhenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine
TidsskriftUgeskrift for Laeger
StatusE-pub ahead of print - 8. feb. 2021

Fingeraftryk Dyk ned i forskningsemnerne om 'Fæno- eller genotypetest for dihydropyrimidindehydrogenase-mangel før fluoropyrimidinbehandling'. Sammen danner de et unikt fingeraftryk.